ArticleInternational dental journal2026
LOX From Salivary Adenoid Cystic Carcinoma-Associated Fibroblast Promotes Fibrosis in the Pulmonary Pre-metastatic Niche.
Article in International dental journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Copper homeostasis and cuproptosis rewire the tumor microenvironment: mechanisms, immune modulation, and therapeutic opportunities.Journal of hematology & oncology · 2026Review
- Cell type-resolved analysis identifies LOXL2⁺ fibroblasts as key drivers of malignant stromal remodeling in hepatocellular carcinoma.Discover oncology · 2026Article
- The extracellular matrix in inflammation and cancer.Molecular biomedicine · 2026Review
- Role of cancer-associated fibroblast-derived exosomes in pancreatic cancer: clinical therapeutic potential and targeting challenges.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsMetastasis is the primary cause of cancer-related mortality. Carcinoma-associated fibroblasts (CAFs) critically promote lung metastasis in salivary adenoid cystic carcinoma (SACC). CAFs within metastatic organs, often termed metastasis-associated fibroblasts (MAFs), drive extracellular matrix (ECM) remodelling during metastasis. Understanding early ECM remodelling events in the metastatic niche may offer crucial insights for inhibiting metastasis. However, the specific mechanisms through which SACC-associated CAFs regulate lung ECM remodelling remain poorly understood.
methodsCAFs and collagen deposition in murine tissues were visualised using H&E and picrosirius red staining. The role of lysyl oxidase (LOX) in CAF-mediated collagen cross-linking and its underlying molecular mechanisms were examined through western blotting, immunofluorescence staining and collagen contraction assays.
resultsIn this study, we showed that CAFs enhanced collagen cross-linking, leading to stromal fibrosis during the establishment of the pre-metastatic niche and subsequent SACC lung metastasis. LOX, a copper-dependent enzyme crucial for collagen cross-linking and secreted by CAFs, promotes the activation of lung MAFs and increases their collagen I expression. MAF activation is facilitated by LOX, which induces YAP expression and its nuclear translocation. β-Aminopropionitrile, a specific LOX inhibitor, effectively suppressed fibroblast activation and reduced nuclear YAP expression.
conclusionsOur findings indicate that soluble LOX secreted by CAFs promotes metastatic progression through the induction of pulmonary fibrosis. Targeting this LOX-mediated pathway may represent a promising therapeutic strategy for preventing lung metastasis in patients with SACC. Furthermore, given the complexity of metastasis, future studies should investigate how fibrosis influences key stages of metastatic colony formation, including the extravasation and dormancy of circulating tumour cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.